Inter Pharma Public (IP) Fundamentals 2026 — P/E 23.4x, Revenue Analysis | SniperIQ
Inter Pharma Public (IP) is a TH-listed Healthcare company in Biotechnology with a market capitalization of ฿3.1B, trading at ฿5.15 on the SET. This SniperIQ fundamentals page covers Inter Pharma Public's valuation (P/E 23.4x, P/B 1.5x), profitability (net margin 6.0%), revenue (฿2.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Inter Pharma Public's market cap?
Inter Pharma Public (IP) has a market capitalization of approximately ฿3.1B, trading at ฿5.15 on the SET. Market cap moves with the live share price.
What is Inter Pharma Public's P/E ratio?
Inter Pharma Public's trailing twelve-month P/E ratio is 23.4x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Inter Pharma Public?
Inter Pharma Public runs a net profit margin of 6.0%, a gross margin of 41.8%, and an operating margin of 8.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Inter Pharma Public generate?
Inter Pharma Public reported revenue of ฿2.2B for fiscal year 2025, with net income of ฿122M and earnings per share (EPS) of 0.2. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Inter Pharma Public pay a dividend?
Inter Pharma Public offers a trailing dividend yield of about 1.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Inter Pharma Public financially healthy?
Inter Pharma Public carries a debt-to-equity ratio of 0.18x and a current ratio of 1.80x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Inter Pharma Public a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Inter Pharma Public (IP) the key facts are: market cap ฿3.1B, P/E 23.4x, revenue ฿2.2B, 52-week range 3.14-5.25. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Inter Pharma Public's full fundamentals live
Get Inter Pharma Public's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.